These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Energetic characteristics of the new transthyretin variant A25T may explain its atypical central nervous system pathology. Sekijima Y; Hammarström P; Matsumura M; Shimizu Y; Iwata M; Tokuda T; Ikeda S; Kelly JW Lab Invest; 2003 Mar; 83(3):409-17. PubMed ID: 12649341 [TBL] [Abstract][Full Text] [Related]
4. A novel transthyretin variant p.H110D (H90D) as a cause of familial amyloid polyneuropathy in a large Irish kindred. Jimenez-Zepeda VH; Bahlis NJ; Gilbertson J; Rendell N; Porcari R; Lachmann HJ; Gillmore JD; Hawkins PN; Rowczenio DM Amyloid; 2015 Mar; 22(1):26-30. PubMed ID: 25430583 [TBL] [Abstract][Full Text] [Related]
7. Late onset cardiomyopathy as presenting sign of ATTR A45G amyloidosis caused by a novel TTR mutation (p.A65G). Klaassen SHC; Lemmink HH; Bijzet J; Glaudemans AWJM; Bos R; Plattel W; van den Berg MP; Slart RHJA; Nienhuis HLA; van Veldhuisen DJ; Hazenberg BPC Cardiovasc Pathol; 2017; 29():19-22. PubMed ID: 28460244 [TBL] [Abstract][Full Text] [Related]
8. Biophysical analyses of the transthyretin variants, Tyr114His and Tyr116Ser, associated with familial amyloidotic polyneuropathy. Shinohara Y; Mizuguchi M; Matsubara K; Takeuchi M; Matsuura A; Aoki T; Igarashi K; Nagadome H; Terada Y; Kawano K Biochemistry; 2003 Dec; 42(51):15053-60. PubMed ID: 14690414 [TBL] [Abstract][Full Text] [Related]
9. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy. Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615 [TBL] [Abstract][Full Text] [Related]
10. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease. McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941 [TBL] [Abstract][Full Text] [Related]
11. Origin of sporadic late-onset hereditary ATTR Val30Met amyloidosis in Japan. Ueda M; Yamashita T; Misumi Y; Masuda T; Ando Y Amyloid; 2018 Sep; 25(3):143-147. PubMed ID: 30486687 [TBL] [Abstract][Full Text] [Related]
12. D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis? Hammarström P; Sekijima Y; White JT; Wiseman RL; Lim A; Costello CE; Altland K; Garzuly F; Budka H; Kelly JW Biochemistry; 2003 Jun; 42(22):6656-63. PubMed ID: 12779320 [TBL] [Abstract][Full Text] [Related]
13. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met. Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899 [TBL] [Abstract][Full Text] [Related]
14. Clinical and pathological findings in familial amyloid polyneuropathy caused by a transthyretin E61K mutation. Murakami T; Nishimura H; Nagai T; Hemmi S; Kutoku Y; Ohsawa Y; Sunada Y J Neurol Sci; 2017 Oct; 381():55-58. PubMed ID: 28991715 [TBL] [Abstract][Full Text] [Related]
15. Genotypic and phenotypic presentation of transthyretin-related familial amyloid polyneuropathy (TTR-FAP) in Turkey. Durmuş-Tekçe H; Matur Z; Mert Atmaca M; Poda M; Çakar A; Hıdır Ulaş Ü; Oflazer-Serdaroğlu P; Deymeer F; Parman YG Neuromuscul Disord; 2016 Jul; 26(7):441-6. PubMed ID: 27238058 [TBL] [Abstract][Full Text] [Related]
16. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis). Gonzalez-Duarte A; Ulloa-Aguirre A Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963 [TBL] [Abstract][Full Text] [Related]
17. Three patients of transthyretin amyloidosis in a Japanese family with amyloidogenic transthyretin Thr49Ser (p.Thr69Ser) variant. Ikura H; Kitakata H; Endo J; Moriyama H; Sano M; Tsujikawa H; Sawano M; Masuda T; Ohki T; Ueda M; Kosaki K; Fukuda K Eur J Med Genet; 2022 Mar; 65(3):104451. PubMed ID: 35149236 [TBL] [Abstract][Full Text] [Related]
18. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy. Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783 [TBL] [Abstract][Full Text] [Related]
19. Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy. Koike H; Ando Y; Ueda M; Kawagashira Y; Iijima M; Fujitake J; Hayashi M; Yamamoto M; Mukai E; Nakamura T; Katsuno M; Hattori N; Sobue G J Neurol Sci; 2009 Dec; 287(1-2):178-84. PubMed ID: 19709674 [TBL] [Abstract][Full Text] [Related]
20. Tolcapone, a potent aggregation inhibitor for the treatment of familial leptomeningeal amyloidosis. Pinheiro F; Varejão N; Esperante S; Santos J; Velázquez-Campoy A; Reverter D; Pallarès I; Ventura S FEBS J; 2021 Jan; 288(1):310-324. PubMed ID: 32324953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]